TY - JOUR
T1 - Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
AU - SSEV Bioinformatics Working Group
AU - Wang, Li
AU - Kainulainen, Markus H.
AU - Jiang, Nannan
AU - Di, Han
AU - Bonenfant, Gaston
AU - Mills, Lisa
AU - Currier, Michael
AU - Shrivastava-Ranjan, Punya
AU - Calderon, Brenda M.
AU - Sheth, Mili
AU - Mann, Brian R.
AU - Hossain, Jaber
AU - Lin, Xudong
AU - Lester, Sandra
AU - Pusch, Elizabeth A.
AU - Jones, Joyce
AU - Cui, Dan
AU - Chatterjee, Payel
AU - Jenks, M. Harley
AU - Morantz, Esther K.
AU - Larson, Gloria P.
AU - Hatta, Masato
AU - Harcourt, Jennifer L.
AU - Tamin, Azaibi
AU - Li, Yan
AU - Tao, Ying
AU - Zhao, Kun
AU - Lacek, Kristine
AU - Burroughs, Ashley
AU - Wang, Wei
AU - Wilson, Malania
AU - Wong, Terianne
AU - Park, So Hee
AU - Tong, Suxiang
AU - Barnes, John R.
AU - Tenforde, Mark W.
AU - Self, Wesley H.
AU - Shapiro, Nathan I.
AU - Exline, Matthew C.
AU - Files, D. Clark
AU - Gibbs, Kevin W.
AU - Hager, David N.
AU - Patel, Manish
AU - Halpin, Alison L.
AU - McMullan, Laura K.
AU - Lee, Justin S.
AU - Xia, Hongjie
AU - Xie, Xuping
AU - Shi, Pei Yong
AU - Davis, C. Todd
N1 - Publisher Copyright:
© 2022, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
PY - 2022/12
Y1 - 2022/12
N2 - The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccine-mediated protection from disease. To ascertain and rank the risk of VOCs and VOIs, we analyze the ability of 14 variants (614G, Alpha, Beta, Gamma, Delta, Epsilon, Zeta, Eta, Theta, Iota, Kappa, Lambda, Mu, and Omicron) to escape from mRNA vaccine-induced antibodies. The variants show differential reductions in neutralization and replication by post-vaccination sera. Although the Omicron variant (BA.1, BA.1.1, and BA.2) shows the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retain moderate neutralizing activity against that variant. Therefore, vaccination remains an effective strategy during the COVID-19 pandemic.
AB - The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccine-mediated protection from disease. To ascertain and rank the risk of VOCs and VOIs, we analyze the ability of 14 variants (614G, Alpha, Beta, Gamma, Delta, Epsilon, Zeta, Eta, Theta, Iota, Kappa, Lambda, Mu, and Omicron) to escape from mRNA vaccine-induced antibodies. The variants show differential reductions in neutralization and replication by post-vaccination sera. Although the Omicron variant (BA.1, BA.1.1, and BA.2) shows the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retain moderate neutralizing activity against that variant. Therefore, vaccination remains an effective strategy during the COVID-19 pandemic.
UR - http://www.scopus.com/inward/record.url?scp=85135172169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135172169&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-31929-6
DO - 10.1038/s41467-022-31929-6
M3 - Article
C2 - 35896523
AN - SCOPUS:85135172169
SN - 2041-1723
VL - 13
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 4350
ER -